Stem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA; The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Cell Stem Cell. 2020 Oct 1;27(4):663-678.e8. doi: 10.1016/j.stem.2020.07.022. Epub 2020 Sep 4.
Mutant KRAS is a common driver in epithelial cancers. Nevertheless, molecular changes occurring early after activation of oncogenic KRAS in epithelial cells remain poorly understood. We compared transcriptional changes at single-cell resolution after KRAS activation in four sample sets. In addition to patient samples and genetically engineered mouse models, we developed organoid systems from primary mouse and human induced pluripotent stem cell-derived lung epithelial cells to model early-stage lung adenocarcinoma. In all four settings, alveolar epithelial progenitor (AT2) cells expressing oncogenic KRAS had reduced expression of mature lineage identity genes. These findings demonstrate the utility of our in vitro organoid approaches for uncovering the early consequences of oncogenic KRAS expression. This resource provides an extensive collection of datasets and describes organoid tools to study the transcriptional and proteomic changes that distinguish normal epithelial progenitor cells from early-stage lung cancer, facilitating the search for targets for KRAS-driven tumors.
突变型 KRAS 是上皮癌的常见驱动基因。然而,上皮细胞中致癌 KRAS 激活后早期发生的分子变化仍知之甚少。我们在四个样本集中比较了 KRAS 激活后单细胞分辨率的转录变化。除了患者样本和基因工程小鼠模型外,我们还从原代小鼠和人诱导多能干细胞衍生的肺上皮细胞中开发了类器官系统,以模拟早期肺腺癌。在所有四个环境中,表达致癌 KRAS 的肺泡上皮祖细胞 (AT2) 细胞成熟谱系特征基因的表达减少。这些发现证明了我们的体外类器官方法在揭示致癌 KRAS 表达的早期后果方面的效用。该资源提供了广泛的数据集,并描述了类器官工具,用于研究区分正常上皮祖细胞和早期肺癌的转录和蛋白质组变化,有助于寻找 KRAS 驱动肿瘤的靶点。